Researcher from University Hospital of Lyon Reports on Findings in Acute Myeloid Leukemia (Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation).

A recent study conducted at the University Hospital of Lyon explores the use of small molecule menin inhibitors as novel therapeutic agents for acute myeloid leukemia (AML) with specific genetic abnormalities. The study highlights the clinical value of genomic abnormalities in AML and the development of targeted therapies that have improved patient outcomes. Phase 1/2 clinical trials have shown the efficacy and tolerability of menin inhibitors such as SNDX-5613 and KO-539. The research reviews the progress in exploring menin-KMT2A interactions and their potential application in the treatment of acute leukemias. [Extracted from the article]